134419-59-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Tetrahydro-2H-pyran-4-yl methanesulfonate is used as an intermediate in the synthesis of 3,4,5-Trimethoxy-2-nitro Acetophenone (T795510) for its role in creating complex molecular structures. This intermediate is crucial for the development of substituted 4-alkyl-2(1H)-quinazolinones, which are potential cardiotonics, agents that strengthen the contraction of the heart muscle.
Additionally, Tetrahydro-2H-pyran-4-yl methanesulfonate is utilized as an intermediate to synthesize 2-Amino-3,4,5-trimethoxybenzophenones, which are potent tubulin polymerization inhibitors. These inhibitors have potential applications in the treatment of various cancers by disrupting the normal cell division process, thereby preventing tumor growth and progression.

Upstream product

• 2081-44-9 Tetrahydro-pyran-4-ol 
• 124-63-0 methanesulfonyl chloride 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 108-97-4 4-pyrone 

Downstream Products

• 120277-97-6 α-[(2-Nitro-1H-imidazol-1-yl)methyl]-3-oxa-7-azabicyclo4.1.0]heptane-7-ethanol 
• 661481-49-8 4-benzyloxy-2-(tetrahydro-4H-pyran-4-yl-oxy)benzaldehyde 
• 116312-69-7 tetrahydro-2H-pyran-4-yl-hydrazine 
• 1040377-02-3 4-bromo-1-(tetrahydro-2H-pyran-4-yl)- 1H-pyrazole 
• 1218916-45-0 3-(4-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridine 
• 1040377-03-4 1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5 -tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1394930-20-1 2-amino-N-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-[1-(oxan-4-yl)-1H-pyrazol-4-yl]pyridine-3-carboxamide 
• 1394930-47-2 C₂₂H₂₂Cl₂FN₅O₂ 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 233276-38-5 4-methyltetrahydro-2H-pyran-4-carboxylic acid 
• 856255-87-3 4-methyltetrahydro-2H-pyran-4-carbonitrile 
• 110238-91-0 tetrahydropyran-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis

Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood-brain barrier (BBB), critical for stage 2 HAT treatments.

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need for safe, short-course, and low-cost oral treatments to combat this ne

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR

The present invention relates to a pyrrolo(pyrazolo)pyrimidine derivative having efficacy as an LRRK2 inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating degenerative brain diseases, containing the same.

Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis

Calcium dependent protein kinase 1 (CDPK1) is an essential Ser/Thr kinase that controls invasion and egress by the protozoan parasite Toxoplasma gondii. The Gly gatekeeper of CDPK1 makes it exquisitely sensitive to inhibition by small molecule 1H-pyrazolo

PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES

The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain pe

Quinoline Derivatives and Their Use as ALK and ALK L1196M Inhibitors

The present invention relates to quinoline derivatives and a use thereof as inhibitors of ALK and mutated ALK. A pharmaceutical composition containing quinoline derivatives of chemical formula 1 or each of pharmaceutically acceptable salt thereof, has an effect of preventing or treating diseases associated with ALK and ALK L1196M, in other words, proliferative diseases caused by abnormal cell growth and function or behavior thereof.COPYRIGHT KIPO 2019

TAM KINASE INHIBITORS

Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat diseases, such as cancer.

Novel heterocyclic derivative capable of being used as SHP2 inhibitor

The invention relates to a novel heterocyclic derivative capable of being used as an SHP2 inhibitor, specifically relates to a compound shown by a formula I or pharmaceutically acceptable salts thereof, further relates to a use of the compound shown by the formula I or the pharmaceutically acceptable salts thereof and a pharmaceutical composition thereof in drug preparation, and particularly relates to a use in preparation of drugs for treatment, inhibition or prevention of diseases or discomforts mediated by SHP2 activity.